PCN102 Healthcare Resource Utilization (HCRU) and Costs with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIS) and Subsequent Chemotherapy Among Patients with LUNG Cancer
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.239
https://www.valueinhealthjournal.com/article/S1098-3015(20)32495-5/fulltext
Title :
PCN102 Healthcare Resource Utilization (HCRU) and Costs with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIS) and Subsequent Chemotherapy Among Patients with LUNG Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32495-5&doi=10.1016/j.jval.2020.08.239
First page :
Section Title :
Open access? :
No
Section Order :
10185